Mesa Laboratories Inc
NASDAQ:MLAB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Mesa Laboratories Inc
NASDAQ:MLAB
|
480.2m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
49.9B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.2B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Mesa Laboratories Inc
Glance View
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 506 full-time employees. The firm operates through four segments, Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Instruments segment designs, manufactures, and markets quality control hardware and disposable products. The Continuous Monitoring segment develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Mesa Laboratories Inc is 62.4%, which is above its 3-year median of 61.9%.
Over the last 3 years, Mesa Laboratories Inc’s Gross Margin has increased from 61% to 62.4%. During this period, it reached a low of 60.5% on Sep 30, 2023 and a high of 63.1% on Mar 31, 2025.